GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Scivision Biotech Inc (TPE:1786) » Definitions » EV-to-EBIT

Scivision Biotech (TPE:1786) EV-to-EBIT : 21.85 (As of Dec. 15, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Scivision Biotech EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Scivision Biotech's Enterprise Value is NT$5,860.6 Mil. Scivision Biotech's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was NT$268.3 Mil. Therefore, Scivision Biotech's EV-to-EBIT for today is 21.85.

The historical rank and industry rank for Scivision Biotech's EV-to-EBIT or its related term are showing as below:

TPE:1786' s EV-to-EBIT Range Over the Past 10 Years
Min: -594.71   Med: 26.61   Max: 731.41
Current: 21.85

During the past 13 years, the highest EV-to-EBIT of Scivision Biotech was 731.41. The lowest was -594.71. And the median was 26.61.

TPE:1786's EV-to-EBIT is ranked worse than
52.47% of 446 companies
in the Medical Devices & Instruments industry
Industry Median: 20.71 vs TPE:1786: 21.85

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Scivision Biotech's Enterprise Value for the quarter that ended in Sep. 2024 was NT$8,655.9 Mil. Scivision Biotech's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was NT$268.3 Mil. Scivision Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 3.10%.


Scivision Biotech EV-to-EBIT Historical Data

The historical data trend for Scivision Biotech's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scivision Biotech EV-to-EBIT Chart

Scivision Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.84 22.97 25.96 18.50 21.99

Scivision Biotech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.46 21.99 24.95 31.12 32.27

Competitive Comparison of Scivision Biotech's EV-to-EBIT

For the Medical Instruments & Supplies subindustry, Scivision Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scivision Biotech's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Scivision Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Scivision Biotech's EV-to-EBIT falls into.



Scivision Biotech EV-to-EBIT Calculation

Scivision Biotech's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=5860.556/268.266
=21.85

Scivision Biotech's current Enterprise Value is NT$5,860.6 Mil.
Scivision Biotech's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$268.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scivision Biotech  (TPE:1786) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Scivision Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2024 ) =EBIT / Enterprise Value (Q: Sep. 2024 )
=268.266/8655.9348
=3.10 %

Scivision Biotech's Enterprise Value for the quarter that ended in Sep. 2024 was NT$8,655.9 Mil.
Scivision Biotech's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$268.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scivision Biotech EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Scivision Biotech's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Scivision Biotech Business Description

Traded in Other Exchanges
N/A
Address
No. 1, South 1st Road, KEPZ, Kaohsiung, TWN, 806
Scivision Biotech Inc is engaged in the manufacturing and distribution of hyaluronic acid medical supplies in Taiwan. It offers medical devices, including absorbable adhesion barriers, dermal implants, synovial fluid supplements, and intravesical instillation.

Scivision Biotech Headlines

No Headlines